Meditrina has announced the CE Mark approval of its Aveta hysteroscopy system, a significant step towards expanding its global reach in women's healthcare.

The system, which has also received UK Conformity Assessed (UKCA) Mark approval, meets the stringent quality, safety, and efficacy standards required for entry into the EU and the UK markets.

The Aveta hysteroscopy system is designed to enhance the diagnostic and therapeutic capabilities of healthcare professionals dealing with uterine conditions.

Its advanced technology and ergonomic design facilitate minimally invasive procedures, offering improved visualisation and control. This leads to improved patient outcomes and experiences.

Meditrina said its Aveta system has successfully completed its first international procedures in Spain and Denmark, recognising its potential in the diagnosis and treatment of gynaecological conditions.

Furthermore, Meditrina has strategically appointed Ray Gerena as global sales senior vice-president to drive growth and expand its international presence.

Gerena said: “I am honoured to join Meditrina at such an exciting time in its journey. The UKCA and CE Mark approval and successful international procedures represent significant milestones for the company, and I am eager to lead our global sales efforts in bringing our innovative hysteroscopy system to healthcare providers around the world.

“Together, we will continue to make a meaningful impact on women's health.”

With Gerena's extensive experience in strategic sales initiatives, the company will be able to capitalise on new opportunities in the market and create partnerships with healthcare providers across the world.

Meditrina CEO Csaba Truckai said: “We are excited to receive UKCA and CE Mark approval for our hysteroscopy system, as it validates the exceptional quality and performance of our product.”